Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow

Blood (2022) 140 (Supplement 1): 3338–3340.

https://doi.org/10.1182/blood-2022-166748

Published: 2022

Journal Articles

Efficacy of Adoptive Immunotherapy By Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation from Related an Unrelated Donors: A Single Center Retrospective Analysis

Philipp Hemmati, MD, Christin Vogelsänger, Theis Terwey, MD, Christian Jehn, MD, Lam G. Vuong, MD PhD, Igor Wolfgang Blau, MD, Olaf Penack, MD, Bernd Dörken, Renate Arnold, MD PhD

Blood (2016) 128 (22): 4556.

https://doi.org/10.1182/blood.V128.22.4556.4556

Published: 2016

Journal Articles

Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT

Angela Mensen, Korinna Jöhrens, Ioannis Anagnostopoulos, Sonya Demski, Maike Oey, Andrea Stroux, Philipp Hemmati, Jörg Westermann, Olga Blau, Friedrich Wittenbecher, Kamran Movassaghi, Martin Szyska, Sybill Thomas, Bernd Dörken, Carmen Scheibenbogen, Renate Arnold, Il-Kang Na

Blood (2014) 124 (6): 963–972.

https://doi.org/10.1182/blood-2013-11-539031

Published: 2014

Includes: Supplemental data

Journal Articles

Allogeneic Stem Cell Transplantation In Adults With High Risk Acute Lymphoblastic Leukemia (ALL) In 1. Remission (CR1): Promising, But Strongly Influenced By ALL Subtypes

Renate Arnold, MD, Theis H. Terwey, MD, Giang Lam Vuong, MD, Benjamin Ostendorf, MD, Olaf Penack, MD, Gero Massenkeil, MD, Nicola Gökbuget, MD, Philipp Hemmati, MD

Blood (2013) 122 (21): 3409.

https://doi.org/10.1182/blood.V122.21.3409.3409

Published: 2013

Journal Articles

Allogeneic Stem Cell Transplantation For Cytogenetically Normal Acute Myeloid Leukemia: Impact Of FLT3 and NPM1 Mutational Status

Philipp Hemmati, MD, Theis H. Terwey, MD, Lam G. Vuong, PhD, Philipp D le Coutre, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2013) 122 (21): 2104.

https://doi.org/10.1182/blood.V122.21.2104.2104

Published: 2013

Journal Articles

Acute Bone Marrow GvHD Is Associated With Delayed B Cell Neogenesis and Impaired Natural Antibody Response After Allogeneic Hematopoietic Stem Cell Transplantation

Angela Mensen, Korinna Jöhrens, Ioannis Anagnostopoulos, Sonya Demski, Christoph Ochs, Philipp Hemmati, MD, Giang Lam Vuong, MD, Kathrin Rieger, Olga Blau, Jörg Westermann, MD, Bernd Dörken, Carmen Scheibenbogen, Renate Arnold, Il-Kang Na

Blood (2013) 122 (21): 4605.

https://doi.org/10.1182/blood.V122.21.4605.4605

Published: 2013

Journal Articles

Comorbidity Significantly Impairs Quality Of Life In Patients After Allogeneic Hematopoietic Stem Cell Transplantation – Results From The Prospective German Multicenter Validation Trial

Daniel Wolff, MD, Philipp Y. Herzberg, PhD, Steven Z. Pavletic, MD, Pia Heussner, MD, Friederike Mumm, MD, Christina Balsiger, MD, Inken Hilgendorf, MD, Philipp Hemmati, MD, Ernst Holler, MD, PhD, Hildegard T Greinix, MD, Sandra A. Mitchell, PhD

Blood (2013) 122 (21): 2073.

https://doi.org/10.1182/blood.V122.21.2073.2073

Published: 2013

Journal Articles

Differential Expression of SHP-1 Levels in Chronic Phase and Advanced Disease CML and in AML Patients

Jaspal S Kaeda, PhD, Christian Oberender, Daniel Neuman, Theo Kim, MD, Ken I Mills, PhD, Anna Serra, PhD, Philipp Hemmati, MD, Regina Schleede, Tim Overkamp, Frauke Ringel, PhD, Thomas Pretzsch, Seval Turkmen, MD, Michaela Schwarz, MD, Renate Arnold, MD, Bernd Dörken, MD, Philipp le Coutre, MD

Blood (2012) 120 (21): 1449.

https://doi.org/10.1182/blood.V120.21.1449.1449

Published: 2012

Journal Articles

Validation of the NIH Criteria of the Severity Grading of Chronic Gvhd – Results of a Prospective German Multicenter Validation Trial.

Daniel Wolff, Philipp Herzberg, Pia Heussner, Friederike Mumm, Inken Hilgendorf, MD, Stephanie von Harsdorf, MD, Philipp Hemmati, Armin Gerbitz, MD, Michael Schmitt, Ernst Holler, PhD, Hildegard Greinix

Blood (2009) 114 (22): 204.

https://doi.org/10.1182/blood.V114.22.204.204

Published: 2009

Journal Articles

Incidence and Clinical Characteristics of Chronic Graft Versus Host Disease (cGVHD) According to the National Institutes of Health (NIH) Criteria in Patients Transplanted for Acute Myeloid Leukemia (AML).

Arturo Vega, Peter Martus, Theis Terwey, Christian Jakob, MD, Lam G Vuong, Philipp Hemmati, Philipp D. le Coutre, MD, Renate Arnold, MD

Blood (2009) 114 (22): 4639.

https://doi.org/10.1182/blood.V114.22.4639.4639

Published: 2009

Journal Articles

Prognostic Impact of Different High Risk Features in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in First Complete Remission.

Theis Terwey, Philipp Hemmati, Gero Massenkeil, Bernd Dörken, Renate Arnold

Blood (2009) 114 (22): 2303.

https://doi.org/10.1182/blood.V114.22.2303.2303

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation (SCT) in Advanced Chronic Myeloid Leukemia (CML) Patients after Tyrosine Kinase Inhibitor (TKI) Therapy

Philipp D. le Coutre, Philipp Hemmati, Stefan Neuburger, Theis Terwey, Gero Massenkeil, Peter Daniel, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 4419.

https://doi.org/10.1182/blood.V112.11.4419.4419

Published: 2008

Journal Articles

Secondary Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Stefan Neuburger, MD, Philipp Hemmati, MD, Theis Terwey, MD, Gero Massenkeil, MD, Bernd Dörken, MD, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 4297.

https://doi.org/10.1182/blood.V112.11.4297.4297

Published: 2008

Journal Articles

Presence of Bcr-Abl Positive Cells in Peripheral Blood Leukocytes of Immunosuppressed Solid Organ Transplant (SOT) Recipients

Philipp D. le Coutre, MD, Petra Reinke, Ruth Neuhaus, Ralf Trappe, Frauke Ringel, Philipp Hemmati, Bernd Dörken, Peter Daniel

Blood (2008) 112 (11): 3191.

https://doi.org/10.1182/blood.V112.11.3191.3191

Published: 2008

Journal Articles

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Philipp Hemmati, Theis Terwey, Gero Massenkeil, MD, Philipp D. le Coutre, MD, Stefan Neuburger, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3276.

https://doi.org/10.1182/blood.V112.11.3276.3276

Published: 2008

Journal Articles

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Philipp Hemmati, Gero Massenkeil, MD, Theis Terwey, Stefan Neuburger, Philipp D. le Coutre, MD, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3278.

https://doi.org/10.1182/blood.V112.11.3278.3278

Published: 2008

Journal Articles

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

Theis H. Terwey, MD, Gero Massenkeil, MD, Ingo Tamm, MD, Christoph Lutz, MD, Philipp Hemmati, MD, Stefan Neuburger, MD, Bernd Dorken, MD, Renate Arnold, MD

Blood (2006) 108 (11): 3004.

https://doi.org/10.1182/blood.V108.11.3004.3004

Published: 2006

NARROW

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Efficacy of Adoptive Immunotherapy By Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation from Related an Unrelated Donors: A Single Center Retrospective Analysis

Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT

Allogeneic Stem Cell Transplantation In Adults With High Risk Acute Lymphoblastic Leukemia (ALL) In 1. Remission (CR1): Promising, But Strongly Influenced By ALL Subtypes

Allogeneic Stem Cell Transplantation For Cytogenetically Normal Acute Myeloid Leukemia: Impact Of FLT3 and NPM1 Mutational Status

Acute Bone Marrow GvHD Is Associated With Delayed B Cell Neogenesis and Impaired Natural Antibody Response After Allogeneic Hematopoietic Stem Cell Transplantation

Comorbidity Significantly Impairs Quality Of Life In Patients After Allogeneic Hematopoietic Stem Cell Transplantation – Results From The Prospective German Multicenter Validation Trial

Differential Expression of SHP-1 Levels in Chronic Phase and Advanced Disease CML and in AML Patients

Validation of the NIH Criteria of the Severity Grading of Chronic Gvhd – Results of a Prospective German Multicenter Validation Trial.

Incidence and Clinical Characteristics of Chronic Graft Versus Host Disease (cGVHD) According to the National Institutes of Health (NIH) Criteria in Patients Transplanted for Acute Myeloid Leukemia (AML).

Prognostic Impact of Different High Risk Features in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in First Complete Remission.

Allogeneic Stem Cell Transplantation (SCT) in Advanced Chronic Myeloid Leukemia (CML) Patients after Tyrosine Kinase Inhibitor (TKI) Therapy

Secondary Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Presence of Bcr-Abl Positive Cells in Peripheral Blood Leukocytes of Immunosuppressed Solid Organ Transplant (SOT) Recipients

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only